4 November 2026

# Nanosonics appoints independent non-executive director

Nanosonics Limited (ASX: NAN), a global leader in infection prevention, today announces the appointment of Julien Sauvagnargues as an independent non-executive director of Nanosonics Limited, effective 1 December 2026.

Mr Sauvagnargues is a globally experienced MedTech and Consumer executive with a strong track record in commercial growth, operational improvement and business transformation. He has more than two decades of experience with global medical technology company, Olympus, where he held progressively senior leadership roles across Europe and North America.

Most recently, he served as President and CEO, Americas Region, at Olympus Corporation, where he led the company's largest geographic region, overseeing a US$2.8 billion business and more than 4,000 employees. Olympus is a leading manufacturer of optical and digital precision technology and is widely regarded as the global leader in flexible endoscopy.

"We are delighted to welcome Julien to the Nanosonics Board. His extensive global MedTech, commercial and operational leadership experience will be valuable as we continue to grow and strengthen our Trophon business and launch the CORIS System. Julien also brings deep endoscopy expertise from more than two decades at Olympus, including as President and CEO of its Americas business. His understanding of endoscopy customers will provide valuable insight as Nanosonics establishes a significant new growth platform in endoscope reprocessing," said Steve Sargent, Chairman of Nanosonics.

"I have been very impressed by Nanosonics' infection prevention technology, and I am delighted to join the Nanosonics Board at an important stage in its development as it becomes a multi-platform company. Nanosonics has established a strong foundation through trophon and is now broadening its opportunity with the CORIS System. I look forward to working with the Board and management team and contributing my experience as the Company continues to advance these platforms and serve healthcare customers globally," said Mr Sauvagnargues.

Mr Sauvagnargues currently serves on the Board of Directors for the Pennsylvania Chamber of Business and Industry and is on the Advisory Board of AI-powered remote patient monitoring company, Somatix, Inc. He holds a Master's in Business and Corporate Finance from EDHEC Business School in France and a Masters in Technology and Management from CentraleSupelec. A French native, he is based in Pennsylvania, US.

**For more information, please contact:**

Catherine Strong, Head of Investor Relations and Corporate Communications
+61 (0)406 759 268, c.strong@nanosonics.com

Authorised by the Chair of the Nanosonics Limited Board.